{"id":40636,"date":"2022-06-16T17:02:34","date_gmt":"2022-06-16T17:02:34","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=40636"},"modified":"2026-05-05T16:16:03","modified_gmt":"2026-05-05T20:16:03","slug":"blockchain-in-der-strategieberatung-im-gesundheitswesen","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/de\/losungen\/sis-blockchain-consulting\/blockchain-in-der-strategieberatung-im-gesundheitswesen\/","title":{"rendered":"Blockchain in Healthcare Strategy Consulting | SIS"},"content":{"rendered":"
\n

Blockchain in der Strategieberatung im Gesundheitswesen<\/h1>\n
\"SIS<\/figure>\n<\/p>\n
\n
\n

The healthcare industry is undergoing a digital revolution<\/strong>, Und blockchain technology<\/strong> is at the forefront of this transformation.<\/p>\n<\/blockquote>\n

Blockchain in healthcare strategy consulting is helping healthcare organizations improve data security, patient privacy, interoperability, and operational efficiency.<\/p>\n

Bei SIS International Forschung<\/a>, we provide strategic insights into how healthcare providers, pharmaceutical companies, and insurers can leverage blockchain to address key industry challenges and drive innovation.<\/p>\n

Was ist Blockchain im Gesundheitswesen?<\/h2>\n

Blockchain in healthcare<\/a> can solve many of the problems the industry faces. Such issues include medical research, medical supply chain, drug integrity, and medical data. Blockchain also addresses the obstacles of interoperability, accessibility, and security. Because of its ability to produce fantastic data efficiency, Blockchain can disrupt healthcare. It can ensure flexible data access, transparency, interconnection, and better security. It is important to note that healthcare and technology are inseparable.<\/p>\n<\/div>\n

Blockchain in Healthcare Strategy Consulting: Where the Real Value Sits<\/h1>\n

Blockchain in healthcare strategy consulting has matured past the proof-of-concept phase. The wins are now operational, narrow, and tied to specific revenue and compliance problems that legacy databases handle poorly.<\/p>\n

The opportunity for Fortune 500 health systems, payers, and life sciences companies is real, but it sits in places most executives overlook. Provider directory accuracy, clinical trial supply provenance, payer-provider claims reconciliation, and credentialing each carry hundreds of millions in friction cost. These are the use cases where distributed ledgers outperform incumbent systems, and they are the entry points for serious capital deployment.<\/p>\n

Where Blockchain in Healthcare Strategy Consulting Creates Defensible Value<\/h2>\n

Three categories carry the strongest economics. Each has named adopters and measurable returns.<\/p>\n

Provider data management.<\/strong> Synaptic Health Alliance, the consortium including Humana, UnitedHealth Group’s Optum, Aetna, and Quest Diagnostics, demonstrated that a shared ledger reduces the cost of maintaining provider directories. Each payer currently calls the same physician offices to verify the same data. A single source of truth removes the duplication. The payer value story is straightforward: lower administrative load, fewer CMS directory accuracy penalties, faster network adequacy filings.<\/p>\n

Pharmaceutical supply chain.<\/strong> The MediLedger Network, with Pfizer, Genentech, Gilead, and AmerisourceBergen, addresses DSCSA serialization compliance. Drug Supply Chain Security Act enforcement requires interoperable, electronic, package-level traceability across the supply chain. A permissioned ledger satisfies the chain-of-custody requirement without forcing competitors to share commercial data. The compliance trigger is what made this use case bankable.<\/p>\n

Clinical trial integrity.<\/strong> Boehringer Ingelheim and IBM piloted blockchain-anchored trial data to address regulatory questions about source data tampering. Real-world evidence submissions and HTA submission evidence packages benefit when audit trails are cryptographically sealed at the point of capture. Payer pushback on launch sequencing often hinges on data provenance. A ledger trail reduces that vector of doubt.<\/p>\n

The Use Cases That Continue to Disappoint<\/h2>\n

Patient-controlled longitudinal health records remain a poor fit. The bottleneck is not data storage. It is clinical workflow, EHR vendor incentives, and HIPAA-aligned identity proofing. A ledger does not solve any of those.<\/p>\n

Generalized interoperability is similarly oversold. FHIR APIs handle the integration layer well enough that a blockchain adds latency without adding trust where trust already exists. The disciplined question for any pilot: does the use case require a trustless environment among parties with misaligned incentives? If the answer is no, a database is the better tool.<\/p>\n

According to SIS International Research, healthcare blockchain initiatives that anchor to a specific compliance trigger or multi-party reconciliation problem reach production at materially higher rates than those framed as broad interoperability platforms.<\/span> Consortium governance, not technology selection, is the variable that separates the two outcomes.<\/span><\/p>\n

The Consortium Governance Question<\/h2>\n

Every successful healthcare blockchain network is a consortium. That makes governance the strategic question, not the technical one. Who controls node admission. Who pays for network operation. How disputes resolve. How a participant exits without orphaning data.<\/p>\n

Hyperledger Fabric and Quorum dominate the permissioned ledger choice in regulated healthcare contexts. The platform decision is secondary. The governance charter, the legal entity structure, and the economic model carry the project. Health systems entering a consortium without a clear answer on data ownership and antitrust posture create risk that surfaces in implementation, not pitch decks.<\/p>\n

A Practical Framework for Investment Decisions<\/h2>\n

The following decision matrix reflects the pattern recognition from blockchain engagements across healthcare, food safety, and financial services.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n
Use Case Type<\/th>\nTrust Problem Present<\/th>\nCompliance Trigger<\/th>\nInvestment Signal<\/th>\n<\/tr>\n<\/thead>\n
Provider directory consortium<\/td>\nYes \u2014 competing payers<\/td>\nCMS accuracy rules<\/td>\nHigh<\/td>\n<\/tr>\n
Pharma serialization<\/td>\nYes \u2014 multi-tier supply<\/td>\nDSCSA<\/td>\nHigh<\/td>\n<\/tr>\n
Clinical trial provenance<\/td>\nModerate<\/td>\nFDA 21 CFR Part 11<\/td>\nSelective<\/td>\n<\/tr>\n
Claims adjudication<\/td>\nYes \u2014 payer-provider<\/td>\nNone direct<\/td>\nSelective<\/td>\n<\/tr>\n
Patient health records<\/td>\nLow \u2014 workflow issue<\/td>\nHIPAA neutral<\/td>\nAvoid<\/td>\n<\/tr>\n
General interoperability<\/td>\nLow \u2014 FHIR exists<\/td>\nNone<\/td>\nAvoid<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research analysis of healthcare blockchain implementations.<\/em><\/p>\n

What the Best Strategic Buyers Do Differently<\/h2>\n

The Fortune 500 health and life sciences leaders capturing returns from this technology share four behaviors.<\/p>\n

They scope the pilot to a single multi-party reconciliation problem with quantified annual cost. They negotiate consortium governance terms before writing technical specifications. They model total cost of ownership against the incumbent process, including the EDI, manual reconciliation, and audit overhead the ledger replaces. They treat the platform choice as reversible and the data model as permanent.<\/p>\n

Buyers who reverse that order, fixating on Hyperledger versus Quorum before defining the trust problem, consume budget without producing decisions.<\/p>\n

Market Entry and Partnership Diligence<\/h2>\n
\"SIS<\/figure>\n

SIS International Research’s competitive intelligence work in healthcare technology adoption indicates that the strategic acquirers in this space prioritize consortium-anchored startups over standalone protocols. The asset value sits in the network of signed participants, not the codebase.<\/span><\/p>\n

For corporate development teams, this changes the diligence question. A blockchain healthcare target is worth what its consortium membership agreements are worth. Code is commodity. Hyperledger is open source. The defensible asset is the legal and commercial agreement among competitors to share a ledger. That is what an acquirer pays for.<\/p>\n

This is also where market entry strategy intersects with technology acquisition. A payer or pharmaceutical manufacturer entering this space through M&A buys network position. Building the same network organically takes years of consortium negotiation that incumbents have already absorbed.<\/p>\n

How SIS Approaches Blockchain in Healthcare Strategy Consulting<\/h2>\n
\"SIS<\/figure>\n

SIS engagements in this category combine B2B expert interviews with senior payer, provider, and life sciences executives, competitive intelligence on consortium membership and platform adoption, and market entry assessments for technology acquirers evaluating blockchain-native targets. The outputs answer specific board-level questions: where to invest, which consortium to join, which target to acquire, and which use cases to deprioritize.<\/p>\n

The decision-grade question for any leadership team evaluating blockchain in healthcare strategy consulting is narrow. Which multi-party trust problem in your operating model carries enough annual cost to justify a permissioned ledger, and what is the governance path to extract that value? When that question has a precise answer, capital deployment follows.<\/p>\n

\u00dcber SIS International<\/h2>\n

SIS International<\/a> offers Quantitative, Qualitative, and Strategy Research. We provide data, tools, strategies, reports, and insights for decision-making. We also conduct interviews, surveys, focus groups, and other Market Research methods<\/a> and approaches. Kontakt<\/a> f\u00fcr Ihr n\u00e4chstes Marktforschungsprojekt.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n